Eli Lilly buys Centessa in $7.8B bet on brain peptides
- Eli Lilly spent $7.8 billion on Centessa to secure its brain peptide pipeline.
- Morgan Stanley predicts wakefulness drugs will hit $16 billion annually by 2035.
- Pharma giants expect orexin therapies to expand into treating depression and addiction.
Eli Lilly is placing its next big commercial bet on the human brain.
The pharmaceutical titan acquired Centessa Pharmaceuticals for $7.8 billion to secure its pipeline of brain-targeted peptides. The deal targets orexin agonists, synthetic compounds that act as the master control switch for wakefulness. By targeting the neurological triggers of sleep and alertness, drugmakers are looking to build their next major therapeutic franchise.
On The Intelligence, coverage highlighted the rapid commercial expansion surrounding these neuropeptides. Current narcolepsy treatments generate roughly $3 billion annually, but Wall Street expects those numbers to skyrocket. Morgan Stanley projects the global market for orexin drugs will reach $16 billion per year by 2035 as clinical applications broaden.
Regulatory momentum is already shifting toward the mechanism. The FDA recently approved Takeda's ovoperextone for narcolepsy, validating decades of underlying neurobiology. The foundation rests on late 1990s findings by Stanford researcher Dr. Emmanuel Mignot, who discovered that genetic mutations blocking orexin signaling caused narcolepsy in dogs - a deficiency later confirmed in humans.
Narcolepsy is only the immediate entry point. Global business writer Shailesh Chitnis reported on The Intelligence that animal trials show orexin pathways also govern motivation and reward processing. That underlying biology has spurred drugmakers to plan trials targeting depression, ADHD, and addiction, though broad human trial results are still years away.
The race for the brain's master switch has officially begun.
Source Intelligence
- Deep dive into what was said in the episodes
Wake-up haul: an Ozempic moment for the brain • Aug 19
- Investment in orexin drugs is surging, exemplified by Eli Lilly's $7.8 billion acquisition of Centessa Pharmaceuticals. Morgan Stanley projects the global market for these wakefulness-regulating treatments will reach $16 billion annually by 2035, up from the current $3 billion.
Also discussed on this episode: (11)
Brain (1)
- Shailesh Chitnis highlights orexin agonists as the pharmaceutical industry's next major class of drugs, mimicking brain peptides that regulate wakefulness. Takeda's recently approved drug ovoperextone targets narcolepsy, which currently affects between 1 in 1,000 and 1 in 2,000 people.
Biology (1)
- Stanford researcher Dr. Emmanuel Mignot discovered the genetic basis of narcolepsy in the late 1990s by studying Dobermans and Labradors. His work revealed that a genetic mutation preventing dogs from responding to orexin caused the sleep disorder.
Mental Health (1)
- Shailesh Chitnis notes that while currently targeted at narcolepsy, orexin regulates reward-seeking behavior and motivation in animal trials. This suggests future applications for treating depression, ADHD, and addiction, though human trials for these conditions remain in early stages.
Startups (3)
- Japan struggles to produce high-value startups, claiming only six of the world's 1,400 unicorns. Ethan Wu points to a severe shortage of late-stage venture capital as a primary barrier to scaling these domestic businesses globally.
- Japanese startups frequently rush to public listings to secure liquidity rather than pursuing mergers. To curb this trend, the Tokyo Stock Exchange will delist companies that fail to maintain a 10 billion yen market cap after five years starting in 2030.
- Japan lacks a single decacorn, whereas regional peers South Korea and Australia boast six and five respectively. Ethan Wu argues that a homegrown ten-billion-dollar firm is vital to act as an active acquirer and anchor for the broader startup ecosystem.
Society (1)
- Cultural aversion severely limits Japan's entrepreneurial pipeline. Ethan Wu highlights a Global Entrepreneurship Monitor survey showing that only 24% of Japanese view entrepreneurship as a desirable career, compared to a global average of 67%.
Psychology (4)
- Procrastination functions as a self-regulatory failure with severe real-world costs. Benjamin Sutherland notes that a 2013 study linked a one-point increase on a five-point procrastination scale to a $15,000 drop in annual household earnings.
- Beyond financial damage, chronic procrastination correlates with poor health and depression. A meta-analysis of 88 studies involving over 63,000 participants across 17 countries confirmed that delaying tasks diminishes self-esteem and directly predicts future depression.
- Cognitive and physical strategies can reduce procrastination. Mental contrasting with implementation intentions helps users overcome task barriers, while physical exercise builds a sense of mastery that boosts confidence to tackle unpleasant jobs.
- Studies show lifestyle and medical links to task avoidance. A 2024 Italian study tied skipping breakfast to higher procrastination, while a 2021 US study on ADHD patients found the stimulant lisdexamfetamine significantly improved executive function and task initiation.